News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,249 Results
Type
Article (14249)
Company Profile (112)
Press Release (254888)
Section
Business (89103)
Career Advice (471)
Deals (15506)
Drug Delivery (65)
Drug Development (38881)
Employer Resources (49)
FDA (6654)
Job Trends (6382)
News (154070)
Policy (14469)
Tag
Academia (495)
Alliances (23420)
Alzheimer's disease (368)
Approvals (6643)
Artificial intelligence (61)
Bankruptcy (144)
Best Places to Work (4521)
Biotechnology (46)
Breast cancer (44)
Cancer (349)
Career advice (415)
Cell therapy (56)
Clinical research (32279)
Collaboration (159)
Compensation (62)
COVID-19 (782)
C-suite (52)
Data (393)
Diabetes (56)
Diagnostics (1355)
Drug pricing (57)
Earnings (32184)
Employer resources (43)
Events (37907)
Executive appointments (173)
FDA (6845)
Funding (107)
Gene therapy (62)
GLP-1 (299)
Government (1360)
Healthcare (3810)
Infectious disease (799)
Inflammatory bowel disease (46)
Interviews (59)
IPO (5923)
Job creations (2056)
Job search strategy (382)
Layoffs (173)
Legal (3448)
Lung cancer (56)
Manufacturing (102)
Medical device (1426)
Medtech (1428)
Mergers & acquisitions (9615)
Metabolic disorders (175)
Neuroscience (475)
NextGen Class of 2024 (1633)
Non-profit (626)
Northern California (456)
Obesity (105)
Opinion (113)
Patents (54)
People (28608)
Pharmaceutical (64)
Phase I (8516)
Phase II (13659)
Phase III (12177)
Pipeline (200)
Policy (46)
Postmarket research (1462)
Preclinical (3423)
Radiopharmaceuticals (121)
Rare diseases (94)
Real estate (2645)
Regulatory (10182)
Research institute (599)
Resumes & cover letters (55)
Southern California (458)
Startups (1637)
United States (4502)
Vaccines (123)
Weight loss (82)
Date
Today (42)
Last 7 days (292)
Last 30 days (1331)
Last 365 days (13358)
2024 (12185)
2023 (15005)
2022 (20350)
2021 (20908)
2020 (19743)
2019 (15471)
2018 (12093)
2017 (14334)
2016 (13499)
2015 (15969)
2014 (12749)
2013 (10848)
2012 (11630)
2011 (12134)
2010 (11111)
Location
Africa (326)
Arizona (42)
Asia (20370)
Australia (2639)
California (1054)
Canada (612)
China (111)
Colorado (50)
Connecticut (47)
Europe (40060)
Florida (159)
Illinois (116)
Indiana (87)
Japan (43)
Kansas (52)
Maryland (164)
Massachusetts (916)
Minnesota (58)
New Jersey (446)
New York (299)
North Carolina (283)
Northern California (456)
Ohio (41)
Pennsylvania (293)
South America (509)
Southern California (458)
Texas (145)
Washington State (78)
269,249 Results for "prolong pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS)
November 13, 2024
·
3 min read
Press Releases
U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study
October 30, 2024
·
3 min read
Thryv Therapeutics to Present Preclinical Data of SGK1 Inhibition in Models of Drug-Induced QT Prolongation at the 2024 Heart Rhythm Society Meeting
Thryv Therapeutics Inc. today announced a poster presentation of SGK1 inhibition in models of Drug-Induced QT prolongation at the 2024 Heart Rhythm Society meeting in Boston, MA.
May 7, 2024
·
1 min read
Press Releases
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
October 10, 2024
·
19 min read
Press Releases
Neurim Pharmaceuticals Receives Positive CHMP Opinion On Slenyto® (Pediatric Prolonged-Release Melatonin) For The Treatment Of Insomnia In Children With Neurogenetic Disorders (NGDs)
July 31, 2024
·
4 min read
Press Releases
MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD
November 7, 2024
·
6 min read
Press Releases
Mycovia Pharmaceuticals Announces Presentation of Results from Three Safety Studies Evaluating VIVJOA® (oteseconazole) in Subjects with Renal or Hepatic Impairment, and the Impact on QT Prolongation at the 2024 IDSOG Annual Meeting
August 1, 2024
·
6 min read
Pharm Country
Origin Life Sciences Abstract Accepted for Presentation at 2024 Military Health System Research Symposium (MHSRS) Discussing Innovative Technologies and Devices for Treatment of Battlefield Wounds in Prolonged Care to Prevent Infection
Origin Life Sciences, Inc. announced that the Company’s abstract, titled: “NO: a Novel, Pathogen-Agnostic Therapy for Treatment-Resistant Wound Infections in the Warfighter,” has been accepted for presentation at 2024 Military Health System Research Symposium.
June 11, 2024
·
6 min read
Yourgene Health Presents Data Demonstrating Successful Fetal Fraction Enrichment in NIPT Workflows Following Prolonged Blood Storage in EDTA Tubes
Yourgene Health plc, a leading international molecular diagnostics group, presented data demonstrating that prolonged storage of blood in EDTA tubes is compatible with non-invasive prenatal testing when using size selection to enrich the fetal fraction.
June 19, 2023
·
3 min read
Drug Development
Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023
Prolong Pharmaceuticals announced that preliminary data from the recently completed Phase 1 clinical study of PP-007 in acute ischemic stroke patients will be presented in the Late-Breaking Science session during ISC 2023 in Dallas, TX and in the forthcoming PAIRS conference in Dubai.
February 9, 2023
·
3 min read
1 of 26,925
Next
